The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues from external customers | 83,679 | 87,010 | 83,043 | - |
| Personnel costs | 58,367 | 53,202 | 52,863 | - |
| Organizational and marketing costs | 15,594 | 11,562 | 39,983 | - |
| Inventory usage | 6,437 | 5,505 | 6,127 | - |
| Clinical studies and publication costs | 2,542 | 2,586 | 2,183 | - |
| Professional services | 3,007 | 2,530 | 2,524 | - |
| Other segment items | 12,254 | 13,957 | 8,580 | - |
| Change in fair value of equity securities | - | - | 3,561 | -240 |
| Net loss | -14,522 | -2,332 | -501 | -21,325 |
| Depreciation and amortization | 3,929 | 3,777 | 3,816 | 33,178 |
| Stock-based compensation expense | 9,776 | 11,406 | 12,100 | 22,387 |
| Net (gains) losses on equity securities | 2,022 | 1,466 | - | - |
| Deferred income taxes | -10 | -907 | 116 | -5,437 |
| Accretion of discounts on marketable investment securities | 454 | 708 | 905 | 2,606 |
| Other | -532 | 129 | -63 | -219 |
| Accounts receivable | -1,075 | -6,272 | -1,911 | 1,307 |
| Prepaid expenses and other current assets | 6,667 | -3,991 | -161 | 4,696 |
| Inventory | 207 | 1,604 | 307 | 231 |
| Operating lease assets | -371 | -356 | -352 | -664 |
| Other assets | 530 | 312 | 41 | 13 |
| Accounts payable | 3,193 | -17 | 1,406 | 1,689 |
| Operating lease liabilities | -172 | -209 | -197 | -869 |
| Accrued compensation | -19,176 | 6,524 | 6,790 | -7,582 |
| Other accrued and current liabilities | 2,755 | -1,032 | 1,428 | 474 |
| Net cash used in operating activities | -22,129 | 26,931 | 22,631 | 14,785 |
| Purchases of marketable investment securities | 55,136 | 37,408 | 58,474 | 92,832 |
| Proceeds from maturities of marketable investment securities | 39,100 | 54,000 | 54,900 | 80,300 |
| Purchases of debt securities classified as held-to-maturity | 0 | 0 | 0 | 5,569 |
| Asset acquisition, net of cash and cash equivalents acquired | - | 1 | 0 | 18,726 |
| Issuance of loan receivable | - | 2,114 | - | - |
| Proceeds from sale of equity securities | 2,681 | 1,533 | - | - |
| Purchases of property and equipment | 12,455 | 7,184 | 14,834 | 14,003 |
| Proceeds from sale of property and equipment | 7 | 5 | 19 | 21 |
| Net cash used in investing activities | -25,803 | 8,831 | -18,389 | -50,809 |
| Proceeds from exercise of common stock options | 322 | 2,092 | 77 | 37 |
| Proceeds from lease incentives received | - | 0 | 0 | 190 |
| Proceeds from issuance of term debt | - | 0 | 0 | 0 |
| Payment of employees taxes on vested restricted stock units and performance-based restricted stock units | 6,598 | 7,368 | 1,185 | 3,104 |
| Proceeds from contributions to the employee stock purchase plan | 1,267 | 714 | 220 | 1,482 |
| Repayment of principal portion of finance lease liabilities | 24 | 27 | 31 | 57 |
| Net cash used in financing activities | -5,033 | -4,589 | -919 | -1,452 |
| Net change in cash and cash equivalents | -52,965 | 31,173 | 3,323 | -37,476 |
| Beginning of period | 116,729 | 34,153 | 119,709 | - |
| End of period | 63,764 | 31,173 | 85,556 | - |
CASTLE BIOSCIENCES INC (CSTL)
CASTLE BIOSCIENCES INC (CSTL)